Drugmakers took big hits last year on failed clinical trials

02/6/2013 | Genetic Engineering & Biotechnology News

The suspension of a Phase IIb trial of Bristol-Myers Squibb's BMS-986094 nucleotide polymerase inhibitor resulted in a $1.8 billion write-off. Other expensive failures include a joint Pfizer-Johnson & Johnson candidate for Alzheimer's disease, an AstraZeneca and Targacept adjunct to antidepressant treatment, and an Eli Lilly & Co. schizophrenia drug.

View Full Article in:

Genetic Engineering & Biotechnology News

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC
Director of Program Development
AdvaMed
Washington DC, DC
Director of System QA
LifeWatch Services, Inc.
Rosemont, IL
Director of Business Development and Membership
AdvaMed
Washington DC, DC
Director, Corporate Counsel
Regeneron
Tarrytown, NY